CytomX Therapeutics, Inc.
CTMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $138 | $101 | $53 | $37 |
| % Growth | 36.4% | 90.4% | 42.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $138 | $101 | $53 | $37 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $83 | $78 | $112 | $114 |
| G&A Expenses | $30 | $30 | $43 | $39 |
| SG&A Expenses | $30 | $30 | $43 | $39 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $113 | $108 | $154 | $153 |
| Operating Income | $25 | -$6 | -$101 | -$116 |
| % Margin | 18.1% | -6.4% | -190.6% | -311% |
| Other Income/Exp. Net | $7 | $10 | $2 | $0 |
| Pre-Tax Income | $32 | $3 | -$99 | -$116 |
| Tax Expense | $0 | $4 | $0 | $0 |
| Net Income | $32 | -$1 | -$99 | -$116 |
| % Margin | 23.1% | -0.6% | -186.8% | -310.5% |
| EPS | 0.38 | -0.008 | -1.48 | -1.26 |
| % Growth | 5,035.1% | 99.5% | -17.5% | – |
| EPS Diluted | 0.38 | -0.008 | -1.48 | -1.26 |
| Weighted Avg Shares Out | 84 | 74 | 66 | 64 |
| Weighted Avg Shares Out Dil | 85 | 74 | 66 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $10 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $3 |
| EBITDA | $27 | -$4 | -$99 | -$113 |
| % Margin | 19.4% | -4.3% | -186% | -303.8% |